| Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy Y Bao, Y Qiao, JE Choi, Y Zhang, R Mannan, C Cheng, T He, Y Zheng, ... Proceedings of the National Academy of Sciences 120 (49), e2314416120, 2023 | 5 | 2023 |
| Discovery of a first-in-class degrader for the lipid kinase PIKfyve C Li, Y Qiao, X Jiang, L Liu, Y Zheng, Y Qiu, C Cheng, F Zhou, Y Zhou, ... Journal of Medicinal Chemistry 66 (17), 12432-12445, 2023 | 5 | 2023 |
| Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer T He, C Cheng, Y Qiao, H Cho, E Young, R Mannan, S Mahapatra, ... Proceedings of the National Academy of Sciences 121 (15), e2322563121, 2024 | 2 | 2024 |
| Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer C Cheng, J Hu, R Mannan, R Bhattacharyya, NJ Rossiter, B Magnuson, ... bioRxiv, 2024 | 1 | 2024 |
| Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response Y Qiao, JW Wotring, Y Zheng, CJ Zhang, Y Zhang, X Jiang, CD Pretto, ... Proceedings of the National Academy of Sciences 120 (30), e2221809120, 2023 | 1 | 2023 |
| Abstract PR010: CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality JC Tien, Y Chang, Y Zhang, J Chou, Y Cheng, X Wang, J Yang, ... Molecular Cancer Therapeutics 23 (6_Supplement), PR010-PR010, 2024 | | 2024 |
| Deletion of the lipid kinase PIKfyve in Kras-driven pancreatic genetically engineered mouse model SN Yee, X Jiang, C Cheng, A Korkaya, R Mannan, R Mehra, Y Qiao, ... Cancer Research 84 (6_Supplement), 4323-4323, 2024 | | 2024 |
| Dual inhibition of PIKfyve and KRAS/MAPK as a potential for therapeutic strategy for pancreatic ductal adenocarcinoma JP Wisniewski, C Cheng, B Jackson, A Korkaya, S Peters, Y Qiao, ... Cancer Research 84 (6_Supplement), 3300-3300, 2024 | | 2024 |
| Targeting lipid metabolism in pancreatic cancer C Cheng, JP Wisniewski, A Korkaya, B Jackson, R Mannan, S Mahapatra, ... Cancer Research 84 (6_Supplement), 2087-2087, 2024 | | 2024 |
| Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy P Borker, Y Bao, Y Qiao, A Chinnaiyan, JE Choi, Y Zhang, R Mannan, ... Cancer Research 84 (6_Supplement), 7479-7479, 2024 | | 2024 |
| Development of the lipid kinase PIKfyve PROTAC degrader against neuroendocrine prostate cancer Y Qiao, C Li, Y Zheng, X Jiang, SN Yee, C Cheng, Y Bao, Y Zhang, ... Cancer Research 84 (6_Supplement), 2898-2898, 2024 | | 2024 |
| CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality JCY Tien, Y Chang, Y Zhang, J Chou, Y Cheng, X Wang, J Yang, ... bioRxiv, 2024 | | 2024 |
| Suggested searches E Axell, J Hu, M Lindberg, AJ Dear, L Ortigosa-Pascual, EA Andrzejewska, ... Perspective, 2024 | | 2024 |
| Preferential cytotoxicity of ESK981 in neuroendocrine prostate cancer Y Zheng, KJ Garcia-Rogers, Y Bao, R Mannan, T He, SN Yee, C Cheng, ... Cancer Research 83 (7_Supplement), 4011-4011, 2023 | | 2023 |
| Androgen blockade confers sensitivity to PIKfyve inhibition in prostate cancer Y Qiao, SN Yee, C Cheng, Y Zheng, J Luo, Y Bao, X Jiang, X Cao, ... Cancer Research 83 (7_Supplement), 5502-5502, 2023 | | 2023 |
| Novel autophagy inhibitor ESK981 potentiates MEK inhibition cytotoxicity in pancreatic cancer C Cheng, J Wisniewski, B Jackson, Y Bao, Y Qiao, CA Lyssiotis, ... Cancer Research 83 (7_Supplement), 1634-1634, 2023 | | 2023 |
| Overcoming acquired resistance to PROTAC degraders T He, C Cheng, A Parolia, A Hopkins, Y Qiao, L Xiao, A Chinnaiyan Cancer Research 83 (7_Supplement), 1685-1685, 2023 | | 2023 |
| Multiomics analysis to uncover the mechanism of radiosensitization of AR-positive triple negative breast cancers with AR inhibition AR Michmerhuizen, AM Pesch, BC Chandler, LM Lerner, C Ward, ... Cancer Research 82 (12_Supplement), 3307-3307, 2022 | | 2022 |
| Elucidating the mechanistic role of ERG in prostate cancer C Cheng, L Xiao, J Tien, C Wang, J Cheng, E Shiau, X Wang, ... Cancer Research 80 (16_Supplement), 1278-1278, 2020 | | 2020 |
| Degradation of ERG transcription factor as a targeted therapy in B-cell and T-cell acute lymphoblastic leukemia X Wang, C Cheng, Y Qiao, L Xiao, C Wang, A Parolia, A Chinnaiyan Cancer Research 78 (13_Supplement), 1945-1945, 2018 | | 2018 |
